Recombinant Human Activin A Hyperactive Protein, CF Summary
Product Specifications
Gly311-Ser426, with modifications
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
BT-ACTAH
Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with Trehalose. |
Reconstitution | Reconstitute the 10 μg size at 100 μg/mL in sterile 4 mM HCl. Reconstitute all other sizes at 500 μg/mL in sterile 4 mM HCl. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
Human Activin A Hyperactive Protein (Catalog # BT-ACTAH) induces cytotoxicity on MCP-11 cells. The ED50 for this effect is 1.00 15.0 ng/mL. The hyperactive Activin A protein has greater bioactivity than Wild Type Activin A.
Human Activin A Hyperactive Protein (Catalog # BT-ACTAH) induces SBE (SMAD-binding element) reporter activity in HEK293 human embryonic kidney cells. The hyperactive Activin A protein has greater bioactivity than Wild Type Activin A.
2 μg/lane of Recombinant Human Activin A Hyperactive Protein (Catalog # BT-ACTAH) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 12-14 kDa and 20-30 kDa, respectively.
Reconstitution Calculator
Background: Activin A
Activin and Inhibin are members of the TGF-beta superfamily of cytokines and are involved in a wide range of biological processes including tissue morphogenesis and repair, fibrosis, inflammation, neural development, hematopoiesis, reproductive system function, and carcinogenesis (1‑7). Activin and Inhibin are produced as precursor proteins. Their amino terminal propeptides are proteolytically cleaved and facilitate formation of disulfide-linked dimers of the bioactive proteins (8, 9). Activins are nonglycosylated homodimers or heterodimers of various beta subunits ( beta A, beta B, beta C, and beta E in mammals), while Inhibins are heterodimers of a unique alpha subunit and one of the beta subunits. Activin A is a widely expressed homodimer of two beta A chains. The beta A subunit can also heterodimerize with a beta B or beta C subunit to form Activin AB and Activin AC, respectively (10). The 14 kDa mature human beta A chain shares 100% amino acid sequence identity with bovine, feline, mouse, porcine, and rat beta A. Activin A exerts its biological activities by binding to the type 2 serine/threonine kinase Activin RIIA which then noncovalently associates with the type 1 serine/threonine kinase Activin RIB/ALK-4 (7, 11). Signaling through this receptor complex leads to Smad activation and regulation of activin-responsive gene transcription (7, 11). The bioactivity of Activin A is regulated by a variety of mechanisms (11). BAMBI, Betaglycan, and Cripto are cell‑associated molecules that function as decoy receptors or limit the ability of Activin A to induce receptor complex assembly (12‑14). The intracellular formation of Activin A can be prevented by the incorporation of the beta A subunit into Activin AC or Inhibin A (3, 10). And the bioavailability of Activin A is restricted by its incorporation into inactive complexes with alpha 2-Macroglobulin, Follistatin, and FLRG (15, 16). Activin A is involved in the differentiation of various cell and tissue types. The induction of definitive endoderm by Activin A is required in differentiation protocols of induced pluripotent stem cells (iPSCs) (17, 18). In vitro models of human gametogenesis use prolonged Activin A supplementation to human embryonic stem cells for differentiation into human primordial germ cell-like cells (19). Activin A can also be used to maintain cells in vitro, as is the case for iPSC-derived nephron cells that can then be used in disease modeling, drug screening and in regenerative medicine (20). Activin A is an important factor for tumor cells to evade the immune system as Activin A can act on surrounding immune cells to decrease their antitumor activity (21). Activin A also promotes migration and growth of tumors, making it a target for cancer therapies (22). Specifically, research has shown that interfering with Activin A activity can assist in overcoming CD8 T-cell exclusion and immunotherapy resistance (23). In bone marrow-derived stem cell transplants for treatment of diabetes, Activin A enhances migration and homing of stem cells towards pancreatic lineage (24). With AI assisted designing, this enigneered rhActivinA shows superior activity compared to the wild type.
- Kumanov, P. et al. (2005) Reprod. Biomed. Online 10:786.
- Maeshima, A. et al. (2008) Endocr. J. 55:1.
- Rodgarkia-Dara, C. et al. (2006) Mutat. Res. 613:123.
- Werner, S. and C. Alzheimer (2006) Cytokine Growth Factor Rev. 17:157.
- Xu, P. and A.K. Hall (2006) Dev. Biol. 299:303.
- Shav-Tal, Y. and D. Zipori (2002) Stem Cells 20:493.
- Chen, Y.G. et al. (2006) Exp. Biol. Med. 231:534.
- Gray, A.M. and A.J. Mason (1990) Science 247:1328.
- Mason, A.J. et al. (1996) Mol. Endocrinol. 10:1055.
- Thompson, T.B. et al. (2004) Mol. Cell. Endocrinol. 225:9.
- Harrison, C.A. et al. (2005) Trends Endocrinol. Metab. 16:73.
- Onichtchouk, D. et al. (1999) Nature 401:480.
- Gray, P.C. et al. (2002) Mol. Cell. Endocrinol. 188:254.
- Kelber, J.A. et al. (2008) J. Biol. Chem. 283:4490.
- Phillips, D.J. et al. (1997) J. Endocrinol. 155:65.
- Schneyer, A. et al. (2003) Endocrinology 144:1671.
- Ghorbani-Dalini, S. et al. (2020) 3 Biotech. 10:215.
- Mennen, R.H. et al. (2022) Reprod Toxicol. 107:44.
- Mishra, S. et al. (2021) Stem Cells. 39:551.
- Tanigawa, S. et al. (2019) Stem Cell Reports 13:322.
- Cangkrama, M. et al. (2020) Trends Mol. Med. 26:1107.
- Ries, A. et al. (2020) Expert Opin. Ther. Targets. 24:985.
- Pinjusic, K. et al. (2022) J. Immunother. Cancer. 10:e004533.
- Dadheech, N. et al. (2020) Stem Cell Res. Ther. 11:327.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human Activin A Hyperactive Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Activin A Hyperactive Protein, CF and earn rewards!
Have you used Recombinant Human Activin A Hyperactive Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image